Evidence map›Paper›PMID 33999959›Full record

ArticlePloS one2021

Structure-activity mapping of ARHGAP36 reveals regulatory roles for its GAP homology and C-terminal domains.

Patricia R Nano, Taylor K Johnson, Takamasa Kudo, Nancie A Mooney, Jun Ni, Janos Demeter, Peter K Jackson, James K Chen

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Internalization of extracellular vesicles fromJournal of extracellular biology · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Patricia R NanoDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America.ORCID 0000-0002-5507-2656
Taylor K JohnsonDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America.ORCID 0000-0001-6373-6232
Takamasa KudoDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America.
Nancie A MooneyDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, United States of America.
Jun NiDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America.ORCID 0000-0002-4479-8494
Janos DemeterDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, United States of America.
Peter K JacksonDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, United States of America.
James K ChenDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, United States of America.ORCID 0000-0002-9220-8436

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Vittorio Sebastiano · 2007 to 2026
$71.4M
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Chemical tools for developmental biologyR35GM127030 · NIGMS · STANFORD UNIVERSITY · PI JAMES K CHEN · 2018 to 2026
$6.3M
Stanford Chem-H Chemistry/Biology Interface Predoctoral Training ProgramT32GM120007 · NIGMS · STANFORD UNIVERSITY · PI BERTOZZI, CAROLYN · 2016 to 2020
$1.2M
Four Laser, 18 Color Cell Sorter in the SSFFS10RR025518 · NCRR · STANFORD UNIVERSITY · PI HERZENBERG, LEONARD A · 2009 to 2009
$500k
BD Canto II RUO CytometerS10RR027431 · NCRR · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2010 to 2010
$236k
NCI NIH HHS P30 CA124435NCI NIH HHS T32 CA009302NCRR NIH HHS S10 RR025518NCRR NIH HHS S10 RR027431NIGMS NIH HHS R35 GM127030NIGMS NIH HHS T32 GM120007
6 · The paper itself

Abstract

ARHGAP36 is an atypical Rho GTPase-activating protein (GAP) family member that drives both spinal cord development and tumorigenesis, acting in part through an N-terminal motif that suppresses protein kinase A and activates Gli transcription factors. ARHGAP36 also contains isoform-specific N-terminal sequences, a central GAP-like module, and a unique C-terminal domain, and the functions of these regions remain unknown. Here we have mapped the ARHGAP36 structure-activity landscape using a deep sequencing-based mutagenesis screen and truncation mutant analyses. Using this approach, we have discovered several residues in the GAP homology domain that are essential for Gli activation and a role for the C-terminal domain in counteracting an N-terminal autoinhibitory motif that is present in certain ARHGAP36 isoforms. In addition, each of these sites modulates ARHGAP36 recruitment to the plasma membrane or primary cilium. Through comparative proteomics, we also have identified proteins that preferentially interact with active ARHGAP36, and we demonstrate that one binding partner, prolyl oligopeptidase-like protein, is a novel ARHGAP36 antagonist. Our work reveals multiple modes of ARHGAP36 regulation and establishes an experimental framework that can be applied towards other signaling proteins.

Indexed as

CiliaGTPase-Activating ProteinsSignal TransductionAnimalsHEK293 CellsHumansMiceNIH 3T3 CellsProtein DomainsProtein IsoformsStructure-Activity RelationshipARHGAP36 protein, humanGTPase-Activating ProteinsProtein Isoforms

Identifiers

PMID33999959
PMCPMC8128262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.